Kyverna Therapeutics Raises $85M in Series B Financing
FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!
Stay updated with breaking news from Vida Ventures. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!
/PRNewswire/ -- A2 Biotherapeutics, Inc. ("A2 Bio") is a biotechnology company focused on the development of a first-in-class, logic-gated Tmod™ CAR T cell...
/PRNewswire/ -- A2 Biotherapeutics, Inc. ("A2 Bio") is a biotechnology company focused on the development of a first-in-class, logic-gated Tmod™ CAR T cell...
It’s the first week of the new year, and the life sciences sector continued the IPO momentum of 2021 as Wall Street welcomed three new biotech companies. Here’s a look at the IPOs of Amylyx Pharmaceuticals, CinCor, and Vigil Neuroscience, which raised a combined $482 million to support work on drugs addressing neurodegenerative and cardiovascular disorders.
Arriving in America flush with ambition rather than cash, these Sabras climbed quickly up the ladder of success.